Answers are grounded in this paper and cite their sources.
Highlights controversies surrounding recombinant activated protein C in septic shock, indicating the need for confirmatory clinical trials and trial transparency.
In this issue of Intensive Care Medicine , the steering committee members of the PROWESS-Shock trial present a balanced discussion of the controversies surrounding recombinant human activated protein C (rhAPC) and the challenges intrinsic to designing an industry-sponsored trial [ 1 ]. The investigators have taken important steps to be transparent about financial conflicts of interest, to safeguard data monitoring and to ensure the validity of statistical analysis. The purpose of the upcoming PROWESS-Shock Trial is to prospectively test rhAPC in a high-risk septic population—those patients with vasopressor-dependent shock for ≥4 h. The need for this trial, years after the regulatory approval of rhAPC for a similar indication, is a cautionary tale that contains important lessons for health care providers who manage patients with sepsis, the pharmaceutical industry and the Food and Drug Administration (FDA).
No takes yet. Share an insight, caveat, or question.
Sweeney et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: